Open Access. Powered by Scholars. Published by Universities.®
Pharmaceutics and Drug Design Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Institution
-
- Chapman University (20)
- Ohio Northern University (8)
- University of Tennessee Health Science Center (7)
- University of Nebraska Medical Center (5)
- University of Nebraska - Lincoln (4)
-
- Kennesaw State University (2)
- The Texas Medical Center Library (2)
- University of Louisville (2)
- Virginia Commonwealth University (2)
- American University in Cairo (1)
- Bentley University (1)
- City University of New York (CUNY) (1)
- Claremont Colleges (1)
- Clark University (1)
- Cleveland State University (1)
- Fordham University (1)
- James Madison University (1)
- Roseman University of Health Sciences (1)
- Seton Hall University (1)
- Thomas Jefferson University (1)
- University of Kentucky (1)
- Keyword
-
- Alzheimer’s disease (4)
- Pharmacokinetics (4)
- Drug delivery (3)
- Antimicrobial resistance (2)
- Blood-brain barrier (2)
-
- Blood–brain barrier (2)
- Breast cancer (2)
- Cancer (2)
- Depression (2)
- Drug development (2)
- Drug discovery (2)
- Molecular Trojan Horse (2)
- Monoclonal antibody (2)
- Nanotechnology (2)
- Transferrin receptor (2)
- 28-day toxicology study (1)
- ART (1)
- Absurdity (1)
- Acquired Immunodeficiency Syndrome (AIDS) (1)
- Acute Leukemia (1)
- Amiodarone (1)
- Annovera (1)
- Antiarrhythmic (1)
- Antibiotic Resistance (1)
- Antibiotic stewardship (1)
- Antibody-drug conjugate (1)
- Antidepressive Agents (1)
- Antigen Presentation (1)
- Antimicrobial use (1)
- Antimicrobials (1)
- Publication Year
- Publication
-
- Pharmacy Faculty Articles and Research (19)
- Pharmacy and Wellness Review (8)
- Theses and Dissertations (ETD) (6)
- Theses & Dissertations (5)
- School of Veterinary and Biomedical Sciences: Dissertations, Theses, and Student Research (3)
-
- Theses and Dissertations (3)
- Dissertations and Theses (Open Access) (2)
- Electronic Theses and Dissertations (2)
- Annual Research Symposium (1)
- Computational and Data Sciences (PhD) Dissertations (1)
- Department of Biochemistry and Molecular Biology Faculty Papers (1)
- Department of Biochemistry: Dissertations, Theses, and Student Research (1)
- Dissertations, Theses, and Capstone Projects (1)
- ENGL 1102 Showcase (1)
- KGI Theses and Dissertations (1)
- Longitudinal Scholar's Project (1)
- Natural & Applied Sciences Faculty Publications (1)
- Physician Assistant Capstones, 2020-current (1)
- Scholarly Undergraduate Research Journal at Clark (SURJ) (1)
- Seton Hall University Dissertations and Theses (ETDs) (1)
- Student Theses 2015-Present (1)
- Symposium of Student Scholars (1)
- Theses and Dissertations--Pharmacy (1)
- Undergraduate Research Posters 2012 (1)
- Publication Type
Articles 61 - 64 of 64
Full-Text Articles in Pharmaceutics and Drug Design
Effectiveness Of Pharmacist-Led Amiodarone Monitoring Services On Improving Adherence To Amiodarone Monitoring Recommendations: A Systematic Review, Dave L. Dixon, Steven P. Dunn, Michael S. Kelly, Timothy R. Mcllarky, Roy E. Brown
Effectiveness Of Pharmacist-Led Amiodarone Monitoring Services On Improving Adherence To Amiodarone Monitoring Recommendations: A Systematic Review, Dave L. Dixon, Steven P. Dunn, Michael S. Kelly, Timothy R. Mcllarky, Roy E. Brown
Pharmacy Faculty Articles and Research
Amiodarone remains the mostly frequently used antiarrhythmic in clinical practice and is most often used to maintain normal sinus rhythm in patients with atrial fibrillation who have failed a rate control strategy. Amiodarone has superior efficacy over other antiarrhythmics, a lower risk of torsade de pointes, and a better cardiovascular safety profile in patients with structural heart disease. However, amiodarone is associated with notable noncardiac toxicities affecting the thyroid, lungs, eyes, liver, and central nervous system. Since 2000, clinicians have been advised to follow amiodarone monitoring guidelines provided by the Heart Rhythm Society. Adherence to these recommendations in clinical practice, …
Effects Of Hepatic Ischemia-Reperfusion Injury On The P-Glycoprotein Activity At The Liver Canalicular Membrane And Blood-Brain Barrier Determined By In Vivo Administration Of Rhodamine 123 In Rats, M. K. Miah, Imam H. Shaik, Ulrich Bickel, Reza Mehvar
Effects Of Hepatic Ischemia-Reperfusion Injury On The P-Glycoprotein Activity At The Liver Canalicular Membrane And Blood-Brain Barrier Determined By In Vivo Administration Of Rhodamine 123 In Rats, M. K. Miah, Imam H. Shaik, Ulrich Bickel, Reza Mehvar
Pharmacy Faculty Articles and Research
Purpose To investigate the effects of normothermic hepatic ischemia-reperfusion (IR) injury on the activity of P-glycoprotein (P-gp) in the liver and at the blood-brain barrier (BBB) of rats using rhodamine 123 (RH-123) as an in vivo marker.
Methods Rats were subjected to 90 min of partial ischemia or sham surgery, followed by 12 or 24 h of reperfusion. Following intravenous injection, the concentrations of RH-123 in blood, bile, brain, and liver were used for pharmacokinetic calculations. The protein levels of P-gp and some other transporters in the liver and brain were also determined by Western blot analysis.
Results P-gp protein …
Development Of Hif-1Α/Hif-1Β Heterodimerization Inhibitors Using A Novel Bioluminescence Reporter Assay System For In Vitro High Throughput Screening And In Vivo Imaging, Yun-Chen Chiang
Dissertations and Theses (Open Access)
Tumor growth often outpaces its vascularization, leading to development of a hypoxic tumor microenvironment. In response, an intracellular hypoxia survival pathway is initiated by heterodimerization of hypoxia-inducible factor (HIF)-1α and HIF-1β, which subsequently upregulates the expression of several hypoxia-inducible genes, promotes cell survival and stimulates angiogenesis in the oxygen-deprived environment. Hypoxic tumor regions are often associated with resistance to various classes of radio- or chemotherapeutic agents. Therefore, development of HIF-1α/β heterodimerization inhibitors may provide a novel approach to anti-cancer therapy. To this end, a novel approach for imaging HIF-1α/β heterodimerization in vitro and in vivo was developed in this study …
Anti-Cancer Drug Screening Of Dual Tubulin And Hsp27 Inhibitors With 2d And 3d Lung Cancer Cell Assays, Janine Maria Naim, Rati Lama
Anti-Cancer Drug Screening Of Dual Tubulin And Hsp27 Inhibitors With 2d And 3d Lung Cancer Cell Assays, Janine Maria Naim, Rati Lama
Undergraduate Research Posters 2012
Cancer is the leading cause of death worldwide. The current treatment options available for lung cancer are limited and have drawbacks such as poor bioavailability, numerous side effects, poor efficacy and drug resistance. 3D model serve as a novel approach for drug screening purposes and the evaluation of compounds in the platform can help identify potent compounds for further in vivo xenograft studies.